Anti-cytokine therapies in T1D: Concepts and strategies
Research output: Contribution to journal › Journal article › Research › peer-review
Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.
Original language | English |
---|---|
Journal | Clinical Immunology |
Volume | 149 |
Issue number | 3 Part A |
Pages (from-to) | 279-85 |
Number of pages | 7 |
ISSN | 1521-6616 |
DOIs | |
Publication status | Published - Dec 2013 |
- Antibodies, Monoclonal, Clinical Trials as Topic, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Immunotherapy, Interleukin-1, Interleukin-12, Interleukin-23, Interleukin-6, T-Lymphocytes, Regulatory, Tumor Necrosis Factor-alpha
Research areas
ID: 113810511